Anaphore (La Jolla, CA) is developing a class of protein therapeutics, Atrimers, to address immune-mediated disease and oncology, closed a $13M Series A bring the total round of financing to $38M. Participants include SR One, Merck Serono Ventures, 5AM Ventures, Apposite Capital and Versant Ventures.